Literature DB >> 24478505

Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: does it have any clinical value?

Estela Giménez1, Beatriz Muñoz-Cobo, Carlos Solano, Paula Amat, David Navarro.   

Abstract

We report that in a population of allogeneic stem cell transplant recipients, determination of the viral doubling time (dt) of the cytomegalovirus (CMV) DNA plasma load predicted the eventual need for inception of preemptive antiviral therapy, whereas the level of the initial plasma CMV DNA load did not. The data thus indicated that determination of the dt of CMV DNA may be useful in the therapeutic management of CMV infection in this clinical setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24478505      PMCID: PMC3911364          DOI: 10.1128/JCM.02571-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation.

Authors:  V C Emery; C A Sabin; A V Cope; D Gor; A F Hassan-Walker; P D Griffiths
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

2.  Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.

Authors:  Margaret L Green; Wendy Leisenring; Daniel Stachel; Steven A Pergam; Brenda M Sandmaier; Anna Wald; Lawrence Corey; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-07       Impact factor: 5.742

Review 3.  How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh; Per Ljungman
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

4.  Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients.

Authors:  Concepción Gimeno; Carlos Solano; José C Latorre; Juan C Hernández-Boluda; María A Clari; María J Remigia; Santiago Furió; Marisa Calabuig; Nuria Tormo; David Navarro
Journal:  J Clin Microbiol       Date:  2008-08-27       Impact factor: 5.948

5.  Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT.

Authors:  N Tormo; C Solano; I Benet; J Nieto; R de la Cámara; J López; A Garcia-Noblejas; B Muñoz-Cobo; E Costa; M A Clari; J C Hernández-Boluda; M J Remigia; D Navarro
Journal:  Bone Marrow Transplant       Date:  2011-01-17       Impact factor: 5.483

6.  Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia.

Authors:  María Ángeles Clari; Dayana Bravo; Elisa Costa; Beatriz Muñoz-Cobo; Carlos Solano; María José Remigia; Estela Giménez; Omar J Benmarzouk-Hidalgo; Pilar Pérez-Romero; David Navarro
Journal:  Diagn Microbiol Infect Dis       Date:  2012-11-20       Impact factor: 2.803

7.  Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center.

Authors:  C Solano; B Muñoz-Cobo; E Giménez; M J Remigia; P Amat; M A Clari; D Bravo; I Benet; J Montoro; D Navarro
Journal:  Bone Marrow Transplant       Date:  2013-01-21       Impact factor: 5.483

Review 8.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

Authors:  M H Zweig; G Campbell
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

9.  Comparative evaluation of three automated systems for DNA extraction in conjunction with three commercially available real-time PCR assays for quantitation of plasma Cytomegalovirus DNAemia in allogeneic stem cell transplant recipients.

Authors:  Dayana Bravo; María Ángeles Clari; Elisa Costa; Beatriz Muñoz-Cobo; Carlos Solano; María José Remigia; David Navarro
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

10.  Clinical significance of low cytomegalovirus DNA levels in human plasma.

Authors:  Jesse Waggoner; Dora Y Ho; Paolo Libiran; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2012-04-18       Impact factor: 5.948

View more
  8 in total

1.  Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood.

Authors:  C Solano; E Giménez; J L Piñana; V Vinuesa; S Poujois; S Zaragoza; M Calabuig; D Navarro
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

2.  The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.

Authors:  E Albert; C Solano; E Giménez; D Focosi; A Pérez; L Macera; J L Piñana; J C H Boluda; F Maggi; D Navarro
Journal:  Bone Marrow Transplant       Date:  2017-10-30       Impact factor: 5.483

3.  When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?

Authors:  C Solano; E Giménez; J L Piñana; J C Hernández-Boluda; P Amat; V Vinuesa; D Navarro
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

4.  Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients.

Authors:  Susanna K Tan; Jesse J Waggoner; Benjamin A Pinsky
Journal:  J Clin Virol       Date:  2015-06-10       Impact factor: 3.168

5.  Immunoprofiling reveals cell subsets associated with the trajectory of cytomegalovirus reactivation post stem cell transplantation.

Authors:  Lauren Stern; Helen M McGuire; Selmir Avdic; Barbara Fazekas de St Groth; David Gottlieb; Allison Abendroth; Emily Blyth; Barry Slobedman
Journal:  Nat Commun       Date:  2022-05-11       Impact factor: 17.694

6.  Early immune surveillance to predict cytomegalovirus outcomes after allogeneic hematopoietic stem cell transplantation.

Authors:  Jintao Xia; Xuejie Li; Genyong Gui; Jian Wu; Shengnan Gong; Yuxin Shang; Jun Fan
Journal:  Front Cell Infect Microbiol       Date:  2022-08-03       Impact factor: 6.073

7.  Identification and Characterization of Epithelial Cell-Derived Dense Bodies Produced upon Cytomegalovirus Infection.

Authors:  Estéfani García-Ríos; María Josefa Rodríguez; María Carmen Terrón; Daniel Luque; Pilar Pérez-Romero
Journal:  Vaccines (Basel)       Date:  2022-08-12

8.  Clinical Application of Variation in Replication Kinetics During Episodes of Post-transplant Cytomegalovirus Infections.

Authors:  I P Lodding; H Sengeløv; C da Cunha-Bang; M Iversen; A Rasmussen; F Gustafsson; J G Downing; J Grarup; N Kirkby; C M Frederiksen; A Mocroft; S S Sørensen; J D Lundgren
Journal:  EBioMedicine       Date:  2015-05-08       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.